Company intelligence / Profile preview

Adelphe

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Adelphe is a biotechnology company focused on the maternal-fetal interface to address critical unmet needs in pregnancy and neonatal health. The company is developing novel therapeutics aimed at preventing preterm birth by modulating the immunological environment between the mother and the fetus. Founded by leading experts in maternal-fetal medicine and immunology, Adelphe leverages proprietary insights into the triggers of labor to create targeted interventions. Their mission is to reduce the global burden of prematurity and improve long-term health outcomes for both mothers and children.

Therapeutic areas: Women's Health
Modalities: Small moleculeBiologicImmunomodulator
Industry: Biotech

Beyond the preview

Go deeper on Adelphe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adelphe.

Explore the full profile